Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $6.72 in the prior trading day, Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $6.48, down -3.57%. In other words, the price has decreased by -$3.57 from its previous closing price. On the day, 2.99 million shares were traded. AQST stock price reached its highest trading level at $6.7151 during the session, while it also had its lowest trading level at $6.39.
Ratios:
Our goal is to gain a better understanding of AQST by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 3.53.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17.
On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’25 when Jung Cassie sold 67,575 shares for $7.01 per share. The transaction valued at 473,701 led to the insider holds 240,771 shares of the business.
Kraus Carl N sold 20,272 shares of AQST for $141,904 on Oct 15 ’25. The Chief Medical Officer now owns 282,475 shares after completing the transaction at $7.00 per share. On Oct 15 ’25, another insider, Boyd Peter E., who serves as the insider of the company, sold 10,000 shares for $7.00 each. As a result, the insider received 70,000 and left with 268,323 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 783909120 and an Enterprise Value of 625931136. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.76. Its current Enterprise Value per Revenue stands at 14.183 whereas that against EBITDA is -12.039.
Stock Price History:
The Beta on a monthly basis for AQST is 1.79, which has changed by 0.18032789 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $7.55, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 16.94%, while the 200-Day Moving Average is calculated to be 72.27%.
Shares Statistics:
The stock has traded on average 2.79M shares per day over the past 3-months and 2866100 shares per day over the last 10 days, according to various share statistics. A total of 120.97M shares are outstanding, with a floating share count of 112.44M. Insiders hold about 7.06% of the company’s shares, while institutions hold 38.52% stake in the company. Shares short for AQST as of 1760486400 were 12252965 with a Short Ratio of 4.39, compared to 1757894400 on 8880063. Therefore, it implies a Short% of Shares Outstanding of 12252965 and a Short% of Float of 11.63.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.56 and -$0.6 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.52, with 2.0 analysts recommending between -$0.4 and -$0.65.
Revenue Estimates
10 analysts predict $12.94M in revenue for. The current quarter. It ranges from a high estimate of $15.17M to a low estimate of $10.79M. As of. The current estimate, Aquestive Therapeutics Inc’s year-ago sales were $13.54MFor the next quarter, 10 analysts are estimating revenue of $13.34M. There is a high estimate of $17.9M for the next quarter, whereas the lowest estimate is $10.82M.
A total of 10 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $50.9M, while the lowest revenue estimate was $40.33M, resulting in an average revenue estimate of $44.98M. In the same quarter a year ago, actual revenue was $57.56MBased on 10 analysts’ estimates, the company’s revenue will be $62.11M in the next fiscal year. The high estimate is $77M and the low estimate is $36.85M.
